Skip to main content
. Author manuscript; available in PMC: 2014 May 27.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007855. doi: 10.1002/14651858.CD007855.pub2

Comparison 4. Pivampicillin/pivmecillinam (Miraxid) versus cephalexin.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Symptomatic infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Persistent infection 1 47 Risk Ratio (M-H, Fixed, 95% CI) 5.75 [0.75, 44.15]
3 Recurrent infection 1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.23, 2.50]
4 Shift to another antibiotic 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Adverse effect: nausea 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Adverse effect: vomiting 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Adverse effect: diarrhea 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Adverse effect: allergy or pruritus 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Adverse effect: prematurely stopping treatment 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Preterm delivery 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Preterm labor 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Neonatal infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13 Neonatal respiratory distress 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14 Admission to the neonatal intensive care unit 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15 Duration of neonatal ventilatory support 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
HHS Vulnerability Disclosure